Back to top
more

Cytosorbents (CTSO)

(Delayed Data from NSDQ)

$1.42 USD

1.42
379,871

+0.10 (7.58%)

Updated Sep 18, 2024 04:00 PM ET

After-Market: $1.41 -0.01 (-0.70%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Fiscal Year End for Cytosorbents Corporation falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 14 22 52 71 12
Receivables 6 6 5 5 4
Notes Receivable 0 0 0 0 0
Inventories 4 3 5 3 2
Other Current Assets 2 2 3 3 2
Total Current Assets 26 34 64 82 21
Net Property & Equipment 10 11 5 2 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 5 6 7 4 3
Total Assets 53 63 90 90 27
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 4 2 3 2 2
Current Portion Long-Term Debt 3 0 0 0 2
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 8 8 10 8 6
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 15 10 14 10 10
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 3 5 0 0 13
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 30 28 27 11 24
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 305 287 283 278 192
Retained Earnings -283 -254 -221 -197 -189
Other Equity 1 2 1 -2 1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 23 35 63 79 3
Total Liabilities & Shareholder's Equity 53 63 90 90 27
Total Common Equity 23 35 63 79 3
Shares Outstanding 44.40 43.60 43.40 43.10 32.40
Book Value Per Share 0.52 0.81 1.44 1.84 0.11

Fiscal Year End for Cytosorbents Corporation falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 8 9 14 8 13
Receivables 8 7 6 6 7
Notes Receivable 0 0 0 0 0
Inventories 4 4 4 3 2
Other Current Assets 1 1 2 2 1
Total Current Assets 22 20 26 19 24
Net Property & Equipment 9 10 10 10 11
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 10 5 5 6 6
Total Assets 53 47 53 48 52
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 3 2 4 3 3
Current Portion Long-Term Debt 0 3 3 1 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 7 8 8 8 7
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 10 13 15 12 10
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 14 2 3 4 5
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 37 28 30 29 28
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 308 306 305 292 290
Retained Earnings -293 -289 -283 -277 -267
Other Equity 2 2 1 3 1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 17 19 23 19 24
Total Liabilities & Shareholder's Equity 53 47 53 48 52
Total Common Equity 17 19 23 19 24
Shares Outstanding 52.70 54.30 44.40 44.30 43.90
Book Value Per Share 0.32 0.35 0.52 0.42 0.55